Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the

Abstract

Recenzenci dokumentu: prof. Dariusz Dudek (Kraków), prof. Stefan Grajek (Poznań)

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society

“…Anticoagulant therapy is particularly important in the periprocedural period in the case of invasive treatment of acute coronary syndrome (ACS). Since the last consensus statement of the Polish expert group for Association on Cardiovascular Interventions of the Polish Cardiac Society published in 2014 [2], new circumstances have occurred that triggered the group to revise the viewpoint: 1) the new European Society of Cardiology guidelines on myocardial revascularization announced in 2018 provided indications for the use of bivalirudin in ACS; 2) new studies were published that provided essential new clinical evidence [3][4][5][6]; and 3) updated bivalirudin reimbursement code now allows for its unlimited use in myocardial infarction (MI) patients in Poland [7]. This is a 5-year update of the recommendations on the use of bivalirudin for percutaneous coronary intervention (PCI) of in ACS, tailored to the Polish healthcare setting.…”